279 related articles for article (PubMed ID: 1857943)
21. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
Salen G; Shefer S; Tint GS
Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
[TBL] [Abstract][Full Text] [Related]
22. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
Heller R; Grau AJ; Schäbitz WR; Schwaninger M
Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
[TBL] [Abstract][Full Text] [Related]
23. [Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects].
Lionnet C; Carra C; Ayrignac X; Levade T; Gayraud D; Castelnovo G; Besson G; Androdias G; Vukusic S; Confavreux C; Zaenker C; De Seze J; Collongues N; Blanc F; Tranchant C; Wallon D; Hannequin D; Gerdelat-Mas A; Brassat D; Clanet M; Zephir H; Outteryck O; Vermersch P; Labauge P
Rev Neurol (Paris); 2014; 170(6-7):445-53. PubMed ID: 24746394
[TBL] [Abstract][Full Text] [Related]
24. Cerebrotendinous xanthomatosis.
Berginer VM; Salen G; Shefer S
Neurol Clin; 1989 Feb; 7(1):55-74. PubMed ID: 2493565
[TBL] [Abstract][Full Text] [Related]
25. [Cerebrotendinous xanthomatosis--a case of brain MRI abnormality and osteoporosis].
Kubota R; Nakagawa M; Nakamura A; Kuriyama M; Osame M
Rinsho Shinkeigaku; 1992 May; 32(5):488-93. PubMed ID: 1333927
[TBL] [Abstract][Full Text] [Related]
26. [A case of cerebrotendinous xanthomatosis with spastic paraparesis, epilepsy, and bradykinesia].
Kondo R; Wakamatsu N; Ishikawa A; Yuasa T; Miyatake T
Rinsho Shinkeigaku; 1991 Jun; 31(6):677-9. PubMed ID: 1934787
[TBL] [Abstract][Full Text] [Related]
27. [A case of cerebrotendinous xanthomatosis with convulsive seizures].
Matsumuro K; Takahashi K; Matsumoto H; Okatsu Y; Kuriyama M
Rinsho Shinkeigaku; 1990 Feb; 30(2):207-9. PubMed ID: 2190743
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.
Berginer VM; Salen G; Shefer S
N Engl J Med; 1984 Dec; 311(26):1649-52. PubMed ID: 6504105
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen G; Steiner RD
J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
[TBL] [Abstract][Full Text] [Related]
30. Genetically and clinically confirmed atypical cerebrotendinous xanthomatosis with normal cholestanol and marked elevations of bile acid precursors and bile alcohols.
DeBarber AE; Schaefer EJ; Do J; Ray JW; Larson A; Redder S; Fowler M; Duell PB
J Clin Lipidol; 2024; 18(3):e465-e476. PubMed ID: 38637260
[TBL] [Abstract][Full Text] [Related]
31. Could steroids mask the diagnosis of cerebrotendinous xanthomatosis?
Siman-Tov T; Meiner V; Gadoth N
J Neurol Sci; 2006 Apr; 243(1-2):83-6. PubMed ID: 16445943
[TBL] [Abstract][Full Text] [Related]
32. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.
Nie S; Chen G; Cao X; Zhang Y
Orphanet J Rare Dis; 2014 Nov; 9():179. PubMed ID: 25424010
[TBL] [Abstract][Full Text] [Related]
33. Cerebrotendinous xanthomatosis as a multisystem disease mimicking premature ageing.
Dotti MT; Salen G; Federico A
Dev Neurosci; 1991; 13(4-5):371-6. PubMed ID: 1817044
[TBL] [Abstract][Full Text] [Related]
34. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations.
Moghadasian MH; Salen G; Frohlich JJ; Scudamore CH
Arch Neurol; 2002 Apr; 59(4):527-9. PubMed ID: 11939886
[TBL] [Abstract][Full Text] [Related]
35. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
[TBL] [Abstract][Full Text] [Related]
36. Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress.
Gonzalez-Cuyar LF; Hunter B; Harris PL; Perry G; Smith MA; Castellani RJ
Redox Rep; 2007; 12(3):119-24. PubMed ID: 17623518
[TBL] [Abstract][Full Text] [Related]
37. Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment.
Alhariri A; Hamilton K; Oza V; Cordoro K; Sobreira NL; Malloy M; Slavotinek A
Am J Med Genet A; 2017 Aug; 173(8):2275-2279. PubMed ID: 28590052
[TBL] [Abstract][Full Text] [Related]
38. Three siblings with Cerebrotendinous Xanthomatosis: a novel mutation in the CYP27A1 gene.
Suh S; Kim HK; Park HD; Ki CS; Kim MY; Jin SM; Kim SW; Hur KY; Kim KW; Kim JH
Eur J Med Genet; 2012 Jan; 55(1):71-4. PubMed ID: 21958693
[TBL] [Abstract][Full Text] [Related]
39. [Effect of LDL-apheresis on a case of Cerebrotendinous Xanthomatosis].
Fukuo Y; Hayama N; Hara K; Terashi A; Seta K
Rinsho Shinkeigaku; 1989 Feb; 29(2):196-201. PubMed ID: 2752648
[TBL] [Abstract][Full Text] [Related]
40. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
